SBFMSunshine Biopharma, Inc.

$6M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M+41.6% YoY

Gross Profit

$3M34.0% margin

Operating Income

-$1M-13.1% margin

Net Income

-$1M-14.2% margin

EPS (Diluted)

$-0.94

QoQ Revenue Growth

-9.3%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$30M

Total Liabilities

$5M

Stockholders' Equity

$25M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+41.6%
Gross Profit	$3M	$2M	+44.0%
Operating Income	-$1M	-$779,000	-42.0%
Net Income	-$1M	-$651,000	-84.0%

SBFM Q3 2024 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena